[Targeted therapies, prognostic and predictive factors in endocrine oncology]. - Archive ouverte HAL Access content directly
Journal Articles Annales d'Endocrinologie Year : 2013

[Targeted therapies, prognostic and predictive factors in endocrine oncology].

(1, 2) , (1, 2, 3) , (4) , (1, 5)
1
2
3
4
5

Abstract

A better understanding of molecular mechanisms responsible for tumorigenesis has allowed the development of targeted drugs designed to improve the outcome of cancer. In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors. Rare cancer network has allowed ongoing phase III trials in malignant pheochromocytoma and adrenocortical carcinoma. However, to date no specific predictive biomarker has yet been identified for a personalized cancer medicine. We review recent advances in endocrine oncology concerning molecular targets identification, targeted therapies and predictive or prognostic markers.
Fichier principal
Vignette du fichier
Hescot_Must_Ultimate_Jul_16.pdf (192.56 Ko) Télécharger le fichier
Vignette du fichier
Fig_HESCOT.pdf (272.28 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00931413 , version 1 (16-05-2014)

Identifiers

Cite

Ségolène Hescot, Eric Baudin, Françoise Borson-Chazot, Marc Lombes. [Targeted therapies, prognostic and predictive factors in endocrine oncology].. Annales d'Endocrinologie, 2013, 74 Suppl 1, pp.S13-22. ⟨10.1016/S0003-4266(13)70017-9⟩. ⟨inserm-00931413⟩
335 View
509 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More